Sanofi-Aventis will partner with privately held Ascenta Therapeutics to develop targeted cancer therapeutics designed to restore tumor cell apoptosis. The licensing and collaboration deal announced June 4 centers around a pair of molecules - MI-773 and MI-519-64 - about to enter preclinical development this year, but also will include joint discovery work. Founded in 2003 and backed by top venture capital firms, including Domain Associates, Enterprise Partners, Soffinnova Ventures and U.S. Venture...